The nonsteroidal effects of diethylstilbestrol: The rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer

Journal of Urology

Volumn 170, Issue 5, 2003, Pages 1703-1708

  Scherr, Douglas S ^a   Pitts Jr , W Reid ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

Androgen antagonists; Diethylstilbestrol; Estrogens, synthetic; Prostatic neoplasms

Indexed keywords

2 METHOXYESTRADIOL; ACETYLSALICYLIC ACID; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; DIETHYLSTILBESTROL; ESTROGEN; FLUTAMIDE; GONADORELIN DERIVATIVE; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ARTERY DISEASE; ASTHENIA; BLOOD VESSEL COMPLIANCE; BONE DENSITY; BONE MINERAL; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DUAL ENERGY X RAY ABSORPTIOMETRY; ERECTILE DYSFUNCTION; ESTROGEN METABOLISM; ESTROGEN THERAPY; FATIGUE; FRACTURE; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; MITOSIS INHIBITION; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIDE EFFECT; THROMBOSIS; TREATMENT FAILURE; VASCULAR DISEASE;

EID: 0141988879     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000077558.48257.3d     Document Type: Review

References (73)

1. Huggins, C. and Hodges, C. V.: Studies on prostatic cancer; effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of prostate. Cancer Res, 1: 293, 1941
2. Byar, D. P. and Corle, D. K.: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr, 7: 165, 1988
3. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med, 311: 1281, 1984
4. Smith, D. C., Redman, B. G., Flaherty, L. E., Li, L., Strawderman, M. and Pienta, K. J.: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology, 52: 257, 1998
5. Cox, R. L. and Crawford, E. D.: Estrogens in the treatment of prostate cancer. J Urol, 154: 1991, 1995
6. Malkowicz, S. B.: The role of diethylstilbestrol in the treatment of prostate cancer. Urology, suppl, 58: 108, 2001
7. Kitahara, S., Umeda, H., Yano, M., Koga, F., Sumi, S., Moriguchi, H. et al: Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J, 46: 659, 1999
8. Robertson, C. N., Roberson, K. M., Padilla, G. M., O'Brien, E. T., Cook, J. M., Kim, C. S. et al: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst, 88: 908, 1996
9. Schulz, P., Link, T. A., Chaudhuri, L. and Fittler, F.: Role of the mitochondrial bcl-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res, 50: 5008, 1990
10. Schneider, M. R., Hartmann, R. W., Sinowatz, F. and Amselgruber, W.: Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity. J Cancer Res Clin Oncol, 112: 258, 1986
11. Loose-Mitchell, D. S. and Stancel, G. M.: Estrogens and progestins. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. Edited by J. G. Hardman and L. E. Limbird. New York: McGraw-Hill, chapt. 58, pp. 1597-1634, 2001
12. Daniell, H. W.: Osteoporosis after orchiectomy for prostate cancer. J Urol, 157: 439, 1997
13. Townsend, M. F., Sanders, W. H., Northway, R. O. and Graham, S. D., Jr.: Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer, 79: 545, 1997
14. Diamond, T., Campbell, J., Bryant, C. and Lynch, W.: The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer, 83: 1561, 1998
15. Riggs, B. L., Khosla, S. and Melton, L. J., 3rd: A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res, 13: 763, 1998
16. Eriksson, S., Eriksson, A., Stege, R. and Carlstrom, K.: Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int, 57: 97, 1995
17. Wei, J., Gravlin, K. and Cooney, K. A.: Re: Osteoporosis after orchiectomy for prostate cancer (letter to the editor). J Urol, 160: 1809, 1998
18. Suzuki, Y., Oishi, Y., Aikawa, K., Wada, T., Yamazaki, H., Hasegawa, N. et al: The risk of osteoporosis after androgen deprivation in patients with prostatic carcinoma. J Urol, suppl, 161: 297, abstract 1141, 1999
19. Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S. and Tashiro, K.: Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int, 86: 449, 2000
20. Smith, M. R.: Osteoporosis during androgen deprivation therapy for prostate cancer. Urology, suppl, 60: 79, 2002
21. Oefelein, M. G., Ricchuiti, V., Conrad, W., Seftel, A., Bodner, D., Goldman, H. et al: Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol, 166: 1724, 2001
22. Stoch, S. A., Parker, R. A., Chen, L., Bubley, G., Ko, Y. J., Vincelette, A. et al: Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab, 86: 2787, 2001
23. Goldray, D., Weisman, Y., Jaccard, N., Merdler, C., Chen, J. and Matzkin, H.: Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH). J Clin Endocrinol Metab, 76: 288, 1993
24. Burton, B. T. and Foster, W. R.: Health implications of obesity: an NIH Consensus Development Conference. J Am Diet Assoc, 85: 1117, 1985
25. Maillefert, J. F., Sibilia, J., Michel, F., Saussine, C., Javier, R. M. and Tavernier, C.: Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol, 161: 1219, 1999
26. Scherr, D., Pitts, W. R., Jr. and Vaughn, E. D., Jr.: Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol, 167: 535, 2002
27. Eriksen, E. F., Brixen, K. and Charles, P.: New markers of bone metabolism: clinical use in metabolic bone disease. Eur J Endocrinol, 132: 251, 1995
28. Belchetz, P. E.: Hormonal treatment of postmenopausal women. N Engl J Med, 330: 1062, 1994
29. Oursler, M. J., Pederson, L., Fitzpatrick, L., Riggs, B. L. and Spelsberg, T.: Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci U S A, 91: 5227, 1994
30. Spelsberg, T. C., Subramaniam, M., Riggs, B. L. and Khosla, S.: The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol Endocrinol, 13: 819, 1999
31. Khosla, S., Melton, L. J., 3rd, Atkinson, E. J., O'Fallon, W. M., Klee, G. G. and Riggs, B. L.: Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab, 83: 2266, 1998
32. Slemenda, C. W., Longcope, C., Zhou, L., Hui, S. L., Peacock, M. and Johnston, C. C.: Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest, 100: 1755, 1997
33. Barrett-Connor, E., Mueller, J. E., von Muhlen, D. G., Laughlin, G. A., Schneider, D. L. and Sartoris, D. J.: Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab, 85: 219, 2000
34. Greendale, G. A., Edelstein, S. and Barrett-Connor, E.: Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res, 12: 1833, 1997
35. Berruti, A., Dogliotti, L., Tucci, M., Tarabuzzi, R., Fontana, D. and Angeli, A.: Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J Urol, 166: 2023, 2001
36. Smith, M. R., McGovern, F. J., Zietman, A. L., Fallon, M. A., Hayden, D. L., Schoenfeld, D. A. et al: Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med, 345: 948, 2001
37. Riggs, B. L., Khosla, S. and Melton, L. J., 3rd: Primary osteoporosis in men: role of sex steroid deficiency. Mayo Clin Proc, suppl, 75: S46, 2000
38. Daniell, H. W.: Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology, suppl, 58: 101, 2001
39. Khosla, S., Atkinson, E. J., Dunstan, C. R. and O'Fallon, W. M.: Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab, 87: 1550, 2002
40. See, W. A., Wirth, M. P., McLeod, D. G., Iversen, P., Klimberg, I., Gleason, D. et al: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol, 168: 429, 2002
41. Verhelst, J., Denis, L., Van Vliet, P., Van Poppel, H., Braeckman, J., Van Cangh, P. et al: Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer. Clin Endocrinol, 41: 525, 1994
42. Abrahamsson, P. A.: Treatment of locally advanced prostate cancer-a new role for antiandrogen monotherapy? Eur Urol, suppl, 39: 22, 2001
43. Burns-Cox, N., Basketter, V., Higgins, B. and Holmes, S.: Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol, 9: 431, 2002
44. Chang, A., Yeap, B., Davis, T., Blum, R., Hahn, R., Khanna, O. et al: Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol, 14: 2250, 1996
45. Newton, C., Slota, D., Yuzpe, A. A. and Tummon, I. S.: Memory complaints associated with the use of gonadotropin-releasing hormone agonists: a preliminary study. Fertil Steril, 65: 1253, 1996
46. Friedman, A. J., Juneau-Norcross, M. and Rein, M. S.: Adverse effects of leuprolide acetate depot treatment. Fertil Steril, 59: 448, 1993
47. Sherwin, B. B. and Tulandi, T.: "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab, 81: 2545, 1996
48. Sternbach, H.: Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry, 155: 1310, 1998
49. Green, H. J., Pakenham, K. I., Headley, B. C., Yaxley, J., Nicol, D. L., Mactaggart, P. N. et al: Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int, 90: 427, 2002
50. Leranth, C., Roth, R. H., Elsworth, J. D., Naftolin, F., Horvath, T. L. and Redmond, D. E., Jr.: Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci, 20: 8604, 2000
51. Pribluda, V. S., Gubish, E. R., Jr., Lavallee, T. M., Treston, A., Swartz, G. M. and Green, S. J.: 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev, 19: 173, 2000
52. Liehr, J. G., Fang, W. F., Sirbasku, D. A. and Ari-Ulubelen, A.: Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem, 24: 353, 1986
53. Martucci, C. P. and Fishman, J.: Impact of continuously administered catechol estrogens on uterine growth and luteinizing hormone secretion. Endocrinology, 105: 1288, 1979
54. LaVallee, T. M., Zhan, X. H., Herbstritt, C. J., Kough, E. C., Green, S. J. and Pribluda, V. S.: 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta. Cancer Res, 62: 3691, 2002
55. Figg, W. D., Kruger, E. A., Price, D. K., Kim, S. and Dahut, W. D.: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs, 20: 183, 2002
56. Schulz, P., Bauer, H. W., Brade, W. P., Keller, A. and Fittler, F.: Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells. Cancer, 48: 2867, 1988
57. Dahllof, B., Billstrom, A., Cabral, F. and Hartley-Asp, B.: Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res, 53: 4573, 1993
58. Aizu-Yokota, E., Ichinoseki, K. and Sato, Y.: Microtubule disruption induced by estradiol in estrogen receptor-positive and -negative human breast cancer cell lines. Carcinogenesis, 15: 1875, 1994
59. Rosenbaum, E., Wygoda, M. and Gips, M.: Diethylstilbestrol is an active agent in prostate cancer patients after failure to complete androgen blockade. J Clin Oncol, suppl., p. 1372, 349a, 2000
60. Farrugia, D., Ansell, W., Singh, M., Philp, T., Chinegwundoh, F. and Oliver, R. T.: Stilboestrol plus adrenal suppression as salvage treatment for patients failing treatment with luteinizing hormone-releasing hormone analogues and orchidectomy. BJU Int, 85: 1069, 2000
61. Orlando, M., Chacon, M., Salum, G. and Chacon, D. R.: Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer. Ann Oncol, 11: 177, 2000
62. Klotz, L., McNeill, I. and Fleshner, N.: A phase 1-2 trial of diethylstilbestrol plus low dose warfarin in advanced prostate carcinoma. J Urol, 161: 169, 1999
63. Pavone-Macaluso, M., Ingargiola, G. B., de Voogt, H., Viggiano, G., Barasolo, E., Lardennois, B. et al: Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761. Prog Clin Biol Res, 243A: 379, 1987
64. Henriksson, P., Edhag, O., Eriksson, A. and Johansson, S. E.: Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer. Br J Urol, 63: 186, 1989
65. Hasui, Y., Marutsuka, K., Nishi, S., Kitada, S., Osada, Y. and Sumiyoshi, A.: The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer. Prostate, 21: 35, 1992
66. Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R. et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med, 348: 1425, 2003
67. Atala, A., Amin, M. and Harty, J. I.: Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone. Urology, 39: 108, 1992
68. Robinson, M. R.: EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate. Prog Clin Biol Res, 260: 101, 1998
69. Peeling, W. B.: Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology, suppl, 33: 45, 1989
70. Bolla, M., Gonzalez, D., Warde, P., Dubois, J. B., Mirimanoff, R. O., Storme, G. et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med, 337: 295, 1997
71. Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D. and Trump, D.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341: 1781, 1999
72. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol, 79: 235, 1997
73. Whitesel, J. A.: The case for diethylstilbestrol. J Urol, 169: 290, 2003